Antiangiogenic therapy in the management of brain tumors: a clinical overview.

Kunnakkat, Saroj; Mathew, Maya; Narayana, Ashwatha

Central to the process of brain tumor development is angiogenesis, which involves a host of molecules and receptors. In recent years, antiangiogenic therapies have been developed and tested for their effectiveness against these tumors. Among them are inhibitors against vascular endothelial growth factor and its receptors, as well as inhibitors targeting the platelet-derived growth factor family, integrins, and histone deacetylase. While many have been shown to be effective with limited toxicity, some tumors are able to adopt escape mechanisms. Further research is needed in the development of effective multi-targeted agents to reduce these effects.

BRAIN tumor treatment; NEOVASCULARIZATION inhibitors; VASCULAR endothelial growth factors; VASCULAR endothelial growth factor receptors; PLATELET-derived growth factor; INTEGRINS; HISTONE deacetylase

Cancer Chemotherapy & Pharmacology, 2012, Vol 70, Issue 3, p353

0344-5704

Academic Journal

10.1007/s00280-012-1926-7